Ontario Hospital Association’s Post

Research underway at Ontario's hospitals can help unlock the secrets of how treatments work and opportunities for advancement. Professor Daniel Drucker and his team at Sinai Health's Lunenfeld-Tanenbaum Research Institute have discovered a gut-brain-immune network that controls inflammation across the body and affects organ health. The research centres on the effects of glucagon-like peptide-1 (GLP-1) receptor agonists, or activators, which clinicians use to treat type 2 diabetes and which have recently proven highly effective for weight loss. “We know from clinical studies that GLP-1 does all this amazing stuff in people, but we don't fully know how it works," said Drucker. Drucker has received some of the world's most prestigious awards in the life sciences for his many findings on GLP-1, including the 2023 VinFuture Emerging Innovation Prize and the 2023 Wolf Prize in Medicine. As well, GLP-1-based diabetes drugs that emerged from Drucker's early research were named 2023 breakthrough of the year by the Science Magazine. Read more about this study: https://lnkd.in/g-sE6vVv #hospitalresearch #diabetes

Health System News Sinai Health Study Identifies New Roles for Glucagon-Like Peptide-1 in the Brain

Health System News Sinai Health Study Identifies New Roles for Glucagon-Like Peptide-1 in the Brain

oha.com

To view or add a comment, sign in

Explore topics